Arovella Therapeutics Limited (ASX:ALA)
Arovella Therapeutics Limited, formerly SUDA Pharmaceuticals Limited, is an Australia-based biotechnology company. The Company focuses on specific disease areas, oncology and conditions that affect the central nervous system. It is focused on developing therapies to treat human disease. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.